Free shipping on all orders over $ 500

GDC-0575

Cat. No. M10476

All AbMole products are for research use only, cannot be used for human consumption.

GDC-0575 Structure
Synonym:

RG7741; ARRY575; AK-687476

Size Price Availability Quantity
1mg USD 60 In stock
5mg USD 135 In stock
10mg USD 230 In stock
25mg USD 460 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

GDC-0575 (ARRY-575, RG7741) is a potent and selective oral inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM. GDC-0575 abrogates DNA damage-induced S and G2–M checkpoints, exacerbates DNA double-strand breaks and induces apoptosis in STS cells. GDC-0575 has a synergistic or additive effect together with gemcitabine.

In vivo, GDC-0575 is active at 25 mg/kg as a single agent, but the efficacy is improved at the higher dose. GDC-0575 effectively blocks tumor growth in the D20 and C002 xenografts, and the effect is maintained for at least 10 days after the final dose is administered.

Protocol (for reference only)
Cell Experiment
Cell lines AML cell lines
Preparation method AML cell lines are seeded at 1×104 cells/well in 96-well plates in triplicate, and subjected to different treatment conditions. After 24 h of incubation with GDC-0575, cell proliferation is measured with the XTT Cell Proliferation Kit II.
Concentrations 100 nM
Incubation time 24 h
Animal Experiment
Animal models Female nude BALB/c mice
Formulation 0.5% w/v methylcellulose and 0.2%v/v Tween 80
Dosages 25 mg/kg, 50 mg/kg
Administration oral gavage
Chemical Information
Molecular Weight 378.27
Formula C16H20BrN5O
CAS Number 1196541-47-5
Solubility (25°C) DMSO 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] A Italiano, et al. Ann Oncol. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in pаtιепts with refractory solid tumors

[2] Zay Yar Oo, et al. Clin Cancer Res. Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo

[3] Alessandro Di Tullio, et al. Nat Commun. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia

Related Checkpoint Products
AZD7762

AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively.

BIBR1532

BIBR1532 is a potent and selective telomerase inhibitor with IC50 of 100 nM. BIBR 1532 inhibits the proliferation of JVM13 leukemia cells with an IC50 of 52 μM, and similar effect also occurs in other leukemia cell lines such as Nalm-1, HL-60, and Jurkat. BIBR1532 is also an inhibitor of TERT, the rate-limiting enzyme in the regulation of telomerase activity.

PF-477736

PF-477736 is a selective checkpoint kinase 1 (Chk1) inhibitor with Ki values of 0.49 nM and 47 nM for CHK1 and CHK2 respectively.

SCH 900776

SCH 900776 (MK-8776) is a highly potent and functionally selective CHK1 inhibitor with IC50 of 3 nM.

Rabusertib (LY2603618)

Rabusertib (LY2603618) is an effective and selective Chk1 inhibitor with an IC50 of 7 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: GDC-0575, RG7741; ARRY575; AK-687476 supplier, Checkpoint, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.